📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-10 19:25
0 analysed today
FollowTelegram
0
Today
151,853
All-time analysed
43,533
Positive
6,742
Negative
92,741
Neutral
8,769
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
24 announcements match the current filters (relevance ≥ 5).
95.13% Shareholders Approve Acquisition of Bristlecone Hospitals Division via Slump Sale
Shareholders of Virinchi Limited have approved the acquisition of the Primary and Secondary Healthcare Business Division (Bristlecone Hospitals brand) from its material subsidiary, Virinchi Health Care Private Limited. The transaction is structured as a slump sale, effectively consolidating these healthcare operations directly into the parent company. While 95.13% of the polled public votes were in favor, the total voter turnout was low at 4.89% of the total share capital. Promoters, holding 39.46% of the company, were considered interested parties and did not participate in the voting.
Confidence: HIGH
What changedThe healthcare business division previously held under a subsidiary is being transferred to the parent company, Virinchi Limited, through a slump sale mechanism.
Why it mattersThis internal restructuring consolidates the healthcare brand and operations, which may simplify the corporate structure but also brings the operational risks of the healthcare segment directly onto the parent's balance sheet.
Votes in favor: 5,242,203Votes against: 268,626Public voter turnout: 8.08%Total shares on record: 112,707,372Transaction value: not disclosed
📅 Short termThe market is likely to view this as a routine internal restructuring; immediate price impact may be limited given the lack of disclosed transaction value.
📈 Long termConsolidation could streamline the 'Bundling and Unbundling' strategy for the healthcare segment, but the company must address the historical volatility in healthcare revenue seen in FY23.
⚠ Risk flags
- Related-party transaction
- Low public voter participation
- Transaction value not disclosed in the voting result
Key Highlights
95.13% of valid votes cast by public non-institutional shareholders were in favor of the acquisition.
Total votes polled amounted to 5,510,829 shares, representing 4.89% of the total 112,707,372 shares.
Promoter group holding 44,475,538 shares abstained from voting due to being interested parties.
The acquisition involves the 'Bristlecone Hospitals' brand and its healthcare business division.
The resolution was passed as an Ordinary Resolution on the last date of the postal ballot, August 10, 2026.
👀 What to Watch
Watch for the disclosure of the transaction value (slump sale consideration) in upcoming filings to assess the impact on the parent company's debt-to-equity ratio, which currently stands at 0.28.
Virinchi to acquire Bristlecone Hospitals division for ₹100 Cr via slump sale
Virinchi Limited has announced the acquisition of the Primary and Secondary Healthcare Business Division (Bristlecone Hospitals brand) from its material subsidiary, Virinchi Health Care Private Limited (VHCPL). The transaction is valued at ₹100 Crores and will be executed as a slump sale effective April 1, 2026. The consideration will be settled by adjusting existing loans and advances provided by Virinchi Limited to the subsidiary. The target division reported a turnover of ₹82.99 Cr and a net loss of ₹33.26 Cr for FY26, indicating a significant turnaround requirement.
Confidence: HIGH
What changedVirinchi is moving the community healthcare business from its subsidiary directly to the parent company's books to create a dedicated AI-first healthcare platform.
Why it mattersThe transaction is material at ~35% of TTM revenue. While it cleans up the subsidiary's debt to the parent, it brings a loss-making unit with declining revenues directly into the listed entity's operations.
Acquisition Value: ₹100 CrValue vs TTM Revenue: 35.21%Target FY26 Revenue: ₹82.99 CrTarget FY26 Net Loss: ₹33.26 CrTarget FY26 Net Worth: ₹-28.11 Cr
📅 Short termThe market may view the acquisition of a loss-making unit with negative net worth from a subsidiary at a ₹100 Cr valuation with caution.
📈 Long termThe company aims to build an AI-first healthcare platform; however, the structural decline in the acquired unit's revenue over the last three years poses a significant execution risk.
⚠ Risk flags
- Related-party transaction
- Acquisition of a loss-making unit
- Negative net worth of the target division
- Declining revenue trend in the acquired business
Key Highlights
Acquisition of Bristlecone Hospitals division for a lumpsum consideration of ₹100 Crores.
Target division revenue has declined by 37.6% over two years, from ₹133.15 Cr in FY24 to ₹82.99 Cr in FY26.
The division reported a negative net worth of ₹28.11 Cr as of FY26, compared to a positive ₹31.67 Cr in FY24.
Transaction will be settled by adjusting inter-company loans rather than a fresh cash outflow.
Remote e-voting for shareholder approval runs from July 12, 2026, to August 10, 2026.
👀 What to Watch
Investors should monitor the voting results on August 12, 2026, and scrutinize the next quarterly results to see how the consolidation of this loss-making unit impacts the parent company's already stressed bottom line (TTM PAT of -₹28 Cr).
₹100 Cr Restructuring: Virinchi to Acquire Bristlecone Hospitals from Subsidiary
Virinchi Limited has approved the acquisition of the 'Bristlecone Hospitals' business division from its material subsidiary, Virinchi Health Care Private Limited (VHCPL), for ₹100 Crores. The transaction is structured as a slump sale and represents approximately 35.2% of Virinchi's TTM revenue of ₹284 Crores. Notably, the consideration will be settled by adjusting existing loans and advances from the parent to the subsidiary, involving no fresh cash outflow. The move aims to consolidate primary and secondary healthcare into an AI-first platform while the subsidiary focuses on tertiary care.
Confidence: HIGH
What changedVirinchi is moving the 'Bristlecone Hospitals' operations from its subsidiary directly onto the parent company's balance sheet through a slump sale.
Why it mattersThis internal restructuring consolidates the healthcare business, allowing the parent company to directly apply its IT and AI capabilities to hospital operations while cleaning up inter-company loans.
Transaction Value: ₹100 CroresValue vs TTM Revenue: ~35.2%VHCPL Turnover (Latest Year): ₹82.99 CroresEffective Date: April 1, 2026Consideration Method: Loan adjustment (No cash)
📅 Short termThe market may focus on the valuation of the related-party transaction and the lack of cash outflow, which preserves liquidity for the loss-making parent company.
📈 Long termThe success depends on whether the 'AI-first' healthcare platform can reverse the declining turnover trend seen in the Bristlecone Hospitals division over the last three years.
⚠ Risk flags
- Related-party transaction
- Declining turnover in the acquired business unit
- Execution risk of AI-integration strategy
Key Highlights
Acquisition of Primary and Secondary Healthcare business for a total value of ₹100 Crores
Transaction value represents ~35.2% of the company's TTM revenue of ₹284 Crores
Target entity turnover has declined over the last three years from ₹133.15 Cr to ₹83.00 Cr
Settlement via adjustment of existing loans and advances, resulting in no fresh cash consideration
Transaction is effective retrospectively from April 1, 2026, subject to shareholder approval
👀 What to Watch
Investors should monitor the upcoming postal ballot for shareholder approval and watch for improvements in healthcare margins as the company integrates its AI-first strategy into these operations.
Rs 100 Cr Slump Sale: Virinchi to Acquire Bristlecone Hospitals Business from Subsidiary
Virinchi Limited's board has approved the acquisition of the 'Bristlecone Hospitals' business division from its material subsidiary, VHCPL, for Rs 100 Crores. The transaction is a slump sale effective from April 1, 2026, and will be settled by adjusting existing loans and advances rather than cash payment. This restructuring aims to consolidate primary/secondary healthcare into the parent company to build an AI-driven healthcare platform. Notably, the target division's turnover has declined significantly over the last three years, from Rs 133.15 Cr to Rs 82.99 Cr.
Confidence: HIGH
What changedVirinchi is moving the primary and secondary healthcare operations from its subsidiary (VHCPL) directly into the parent company via a slump sale.
Why it mattersThis consolidates the healthcare business and cleans up the balance sheet by converting inter-company loans into a direct business asset, while attempting to pivot toward a technology-led healthcare model.
Transaction Value: Rs 100 CroresValue vs TTM Revenue: ~35.2%Target Turnover (Latest Year): Rs 82.99 CroresTarget Turnover (3 Years Ago): Rs 133.15 CroresEffective Date: April 1, 2026
📅 Short termThe market may react to the restructuring and the valuation of the slump sale, though as a non-cash internal transfer, the immediate liquidity impact is minimal.
📈 Long termStructural significance depends on the successful execution of the 'AI-first' healthcare platform and the company's ability to stabilize the declining revenue of the acquired hospital units.
⚠ Risk flags
- Related party transaction
- Declining turnover of the acquired business (down ~38% in 3 years)
- Execution risk in pivoting to an AI-driven healthcare model
Key Highlights
Transaction value of Rs 100 Crores for the Bristlecone Hospitals business division, representing ~35% of TTM revenue
Target turnover declined from Rs 133.15 Cr (3 years ago) to Rs 82.99 Cr in the most recent year
Acquisition is effective retrospectively from April 1, 2026, subject to shareholder approval
Consideration to be settled by adjusting existing loans and advances from Virinchi Limited to VHCPL
Aims to establish an AI-first healthcare platform while parent focuses on tertiary care
👀 What to Watch
Monitor the shareholder approval process and the subsequent integration of the AI-first healthcare strategy into the parent company's financials to see if it can reverse the declining revenue trend of the Bristlecone brand.
Virinchi Seeks Approval for ₹50 Cr Loan and ₹90 Cr in Related Party Transactions
Virinchi Limited has issued a postal ballot notice to seek shareholder approval for three significant financial resolutions. The company intends to provide loans or guarantees up to ₹50 crore to its subsidiary, Virinchi Health Care Private Limited (VHCPL). Furthermore, it is seeking approval for material related party transactions (RPTs) totaling ₹60 crore with VHCPL and ₹30 crore with Vivo Bio Tech Limited, a promoter group entity. The voting period for these resolutions runs from June 15, 2026, to July 14, 2026.
Key Highlights
Proposed loan or guarantee of up to ₹50 crore to subsidiary Virinchi Health Care Private Limited for its principal business activities.
Approval sought for material RPTs with VHCPL up to ₹60 crore, including ₹10 crore for services and ₹50 crore for resource transfers.
Approval sought for material RPTs with promoter group entity Vivo Bio Tech Limited up to ₹30 crore.
E-voting period scheduled from June 15, 2026, to July 14, 2026, with results expected by July 16, 2026.
Management asserts that all proposed transactions are at arm's length and within the ordinary course of business.
👀 What to Watch
Investors should monitor the voting results and scrutinize the terms of the ₹30 crore transaction with the promoter group entity to ensure no value leakage. Additionally, track the performance of the healthcare subsidiary to justify the ₹50 crore capital allocation.
Virinchi Ltd Allots 20 Lakh Equity Shares Following Warrant Conversion
Virinchi Limited has allotted 20,00,000 equity shares of Rs. 10 each following the conversion of warrants issued on a preferential basis. The shares were issued at a price of Rs. 25 per share, which includes a premium of Rs. 15. The company received Rs. 3.75 crore, representing the remaining 75% of the total issue price from nine public shareholders. As a result, the company's total subscribed share capital has increased to Rs. 112.56 crore across 11.25 crore shares.
Key Highlights
Allotment of 20,00,000 equity shares upon conversion of preferential warrants.
Issue price fixed at Rs. 25 per share, including a premium of Rs. 15.
Inflow of Rs. 3.75 crore representing the 75% balance payment for the warrants.
Total paid-up equity capital increased to 11,25,57,372 shares of Rs. 10 each.
Allotment made to 9 public category investors, including Dwight Technologies Private Limited.
👀 What to Watch
Investors should note the capital infusion and the resulting equity dilution. The conversion at Rs. 25 per share provides a benchmark for investor sentiment regarding the company's valuation.
Virinchi FY26 Revenue Drops 7% to ₹286 Cr; Reports Consolidated Net Loss of ₹27.4 Cr
Virinchi Limited reported a challenging FY26 with consolidated revenue declining 7.19% YoY to ₹286.13 crore and a net loss of ₹27.39 crore, compared to a profit of ₹0.48 crore in FY25. The performance was severely impacted by a one-time bad-debt write-off of ₹8.43 crore from a major SaaS client and a 29.55% decline in the IDC & IT Services segment due to US visa restrictions. While the SaaS business grew 15.42% to ₹153.94 crore, the healthcare division saw a 23.2% revenue drop, though it managed a marginal EBIT turnaround to ₹0.15 crore.
Key Highlights
Consolidated FY26 revenue fell 7.19% YoY to ₹286.13 crore with a net loss of ₹27.39 crore.
A one-time write-off of ₹8.43 crore (USD 890,530) from QC Holdings significantly hit Q4 and FY26 profitability.
IDC & IT Services revenue declined 29.55% to ₹40.37 crore, resulting in an EBIT loss of ₹2.37 crore due to US visa challenges.
Healthcare segment revenue dropped 23.20% to ₹79.99 crore, but achieved a marginal EBIT of ₹0.15 crore vs a loss in FY25.
Promoter acquired a 49% stake in the healthcare subsidiary via fresh capital infusion in March 2026.
👀 What to Watch
Investors should exercise caution as the company has swung into a significant consolidated loss and faces structural headwinds in its IT services segment. The stock's recovery depends on the successful turnaround of the healthcare business and the stability of the SaaS segment's recurring revenue without further write-offs.
Virinchi FY26 Results: Consolidated Revenue Down 19%, Swings to Net Loss of ₹14.33 Cr
Virinchi Limited reported a weak set of consolidated financial results for the fiscal year ended March 31, 2026. Consolidated revenue from operations declined by 18.8% YoY to ₹244.36 crore, while the company swung to a net loss of ₹14.33 crore from a profit of ₹12.61 crore in the previous year. Although the standalone entity remained profitable with a net profit of ₹13.66 crore, the consolidated performance was severely impacted by losses in subsidiary operations and high depreciation costs of ₹55.41 crore.
Key Highlights
Consolidated revenue from operations decreased to ₹244.36 crore in FY26 from ₹301.13 crore in FY25.
Reported a consolidated net loss of ₹14.33 crore compared to a net profit of ₹12.61 crore in the previous fiscal.
Consolidated EPS turned negative at ₹(1.38) for the year, down from ₹1.52 in FY25.
SaaS Business (US Fintech) revenue grew 15.5% YoY to ₹153.94 crore, providing a partial offset to declines in other segments.
Net cash generated from operating activities fell sharply to ₹20.99 crore from ₹43.98 crore in the prior year.
👀 What to Watch
Investors should exercise caution as the company has moved from profitability to a significant consolidated loss, primarily due to underperforming subsidiaries. Monitor the SaaS segment's growth and management's plan to turn around the healthcare and IT services divisions.
Virinchi Reports FY26 Consolidated Net Loss of ₹29.98 Cr as Revenue Declines 18.8%
Virinchi Limited reported a significant downturn in its consolidated financial performance for the fiscal year ended March 31, 2026. Consolidated revenue fell by 18.8% to ₹244.36 crore compared to ₹301.13 crore in the previous year. The company swung from a net profit of ₹15.95 crore in FY25 to a substantial net loss of ₹29.98 crore in FY26. While the SaaS business remained profitable, losses in IDC & IT services and Payment & Credit services, along with high finance costs, severely impacted the bottom line.
Key Highlights
Consolidated revenue decreased to ₹244.36 crore in FY26 from ₹301.13 crore in FY25
Reported a consolidated net loss of ₹29.98 crore against a profit of ₹15.95 crore in the previous fiscal
The SaaS Business (US Fintech) was the primary revenue driver at ₹153.94 crore but saw segment results drop to ₹13.18 crore
Finance costs remained high at ₹32.97 crore, further straining profitability
The company allotted 61.50 lakh equity shares during Q4 FY26 following the conversion of warrants
👀 What to Watch
Investors should exercise caution as the company has moved into a significant loss-making position on a consolidated basis. The sharp decline in revenue and losses across multiple business segments suggest operational challenges that require a clear turnaround strategy.
Virinchi Limited Allots 9.10 Lakh Equity Shares on Warrant Conversion
Virinchi Limited has approved the allotment of 9,10,476 equity shares following the conversion of warrants previously issued on a preferential basis. The shares were issued at a price of Rs. 28 per share, which includes a premium of Rs. 18. The company received the remaining 75% application money amounting to approximately Rs. 1.91 crore from IT Peer Technologies LLC. Consequently, the total paid-up share capital of the company has increased to Rs. 110.55 crore.
Key Highlights
Allotment of 9,10,476 equity shares of Rs. 10 face value each
Issue price fixed at Rs. 28 per share, including a premium of Rs. 18
Receipt of Rs. 1,91,19,996 representing the 75% balance payment for conversion
Total issued and subscribed share capital increased to 11,05,57,372 equity shares
Allotment made to IT Peer Technologies LLC under the Public category
👀 What to Watch
Investors should account for the minor equity dilution resulting from this warrant conversion. The focus should remain on the company's utilization of these funds for future growth and operational expansion.
Virinchi Ltd Allots 8.5 Lakh Equity Shares to Promoter Group on Warrant Conversion
Virinchi Limited has successfully converted 8,50,000 warrants into equity shares for Vivo Bio Tech Limited, a promoter group entity. The shares were issued at a price of Rs. 28 per share, including a premium of Rs. 18. The company received the remaining 75% application money totaling Rs. 1.78 crore. This move increases the total issued and subscribed share capital to approximately Rs. 109.65 crore across 10.96 crore shares.
Key Highlights
Allotment of 8,50,000 equity shares of Rs. 10 face value each.
Conversion price set at Rs. 28 per share, including a premium of Rs. 18.
Receipt of Rs. 1,78,50,000 representing the 75% balance of the issue price.
Allotment made to Vivo Bio Tech Limited, part of the Promoter Group.
Post-allotment share capital stands at 10,96,46,896 equity shares.
👀 What to Watch
The conversion of warrants by a promoter group entity indicates long-term commitment and confidence in the company's prospects. Investors should monitor the impact of this equity dilution on earnings per share (EPS) in upcoming quarters.
Virinchi Ltd Subsidiary Stake Diluted to 51% Following •7.83 Cr Promoter Investment
Virinchi Limited's subsidiary, Virinchi Health Care Private Limited (VHPL), has allotted 52.22 lakh equity shares to promoter Viswanath Kompella for a total consideration of •7.83 crore. This transaction, executed via warrant conversion at •15 per share, has reduced Virinchi Limited's stake in the subsidiary from 100% to 51%. VHPL is a significant contributor to the group, accounting for 30.73% of the consolidated turnover in FY24-25. While the company remains a subsidiary, the substantial 49% minority interest now held by the promoter will impact future consolidated net profit attributable to shareholders.
Key Highlights
Promoter Viswanath Kompella acquired a 49% stake in VHPL for •7.83 crore
Virinchi Limited's ownership in the healthcare subsidiary diluted from 100% to 51%
VHPL contributed •92.54 crore (30.73%) to consolidated revenue in FY2024-25
The allotment was based on an independent enterprise valuation of •312.08 crore for VHPL
A total of 52,22,000 warrants were converted into equity shares as of March 9, 2026
👀 What to Watch
Investors should assess if the •312 crore valuation for the healthcare business is fair and monitor how the 49% stake dilution affects the parent company's bottom line. The direct capital infusion into the subsidiary by the promoter may signal growth plans but also increases related-party involvement.
Virinchi Ltd Allots 13.15 Lakh Equity Shares to Promoter Group on Warrant Conversion
Virinchi Limited has successfully allotted 13,15,715 equity shares to Vivo Bio Tech Limited, a promoter group entity, following the conversion of warrants issued on a preferential basis. The shares were issued at a price of Rs. 28 per share, which includes a premium of Rs. 18. The company received the remaining 75% application money, totaling approximately Rs. 2.76 crore, to complete the conversion. This move increases the total issued and subscribed share capital to Rs. 108.80 crore, representing 10,87,96,896 equity shares.
Key Highlights
Allotment of 13,15,715 equity shares to Promoter Group entity Vivo Bio Tech Limited
Issue price of Rs. 28 per share including a premium of Rs. 18 per share
Receipt of Rs. 2,76,30,015 representing the final 75% payment for warrant conversion
Total paid-up share capital increased to Rs. 108,79,68,960 divided into 10.88 crore shares
👀 What to Watch
The conversion of warrants by a promoter group entity is a positive signal indicating long-term commitment and confidence in the company's prospects. Investors should monitor the utilization of the newly raised capital and its impact on the company's debt-to-equity ratio.
Virinchi Shareholders Approve Related Party Investment and Warrant Issue for Healthcare Subsidiary
Virinchi Limited shareholders have approved two major special resolutions through a postal ballot concluded on February 23, 2026. The resolutions facilitate investment by a related party into Virinchi Health Care Private Limited, a 100% subsidiary, and the issuance of convertible equity warrants by the same entity. Both proposals received strong support from public shareholders, with over 92% voting in favor. This move is expected to provide necessary capital for the healthcare division's operations or expansion.
Key Highlights
Approval for related party investment in 100% subsidiary Virinchi Health Care Private Limited
Issuance of convertible equity warrants by the healthcare subsidiary approved
Resolution 1 (Investment) passed with 92.7% majority representing 2,558,985 votes in favor
Resolution 2 (Warrants) passed with 92.61% majority representing 2,556,489 votes in favor
Promoters and promoter group abstained from voting as they were interested parties
👀 What to Watch
Investors should monitor the specific terms and valuation of the investment and warrants to understand the impact on the subsidiary's ownership structure. This capital infusion could be a precursor to scaling the healthcare business.
Virinchi Ltd Allots 20.7 Lakh Equity Shares to Promoter Group at Rs 28 Per Share
Virinchi Limited has successfully allotted 20,70,000 equity shares to Vivo Bio Tech Limited, a member of the Promoter Group, following the conversion of warrants. The allotment was executed at an issue price of Rs. 28 per share, which includes a premium of Rs. 18. The company received the remaining 75% of the application money, totaling approximately Rs. 4.35 crore, to complete the conversion. This move increases the company's total paid-up share capital to Rs. 107.48 crore, represented by over 10.74 crore shares.
Key Highlights
Allotment of 20,70,000 equity shares to Promoter Group entity Vivo Bio Tech Limited
Conversion price set at Rs. 28 per share, including a premium of Rs. 18 per share
Receipt of Rs. 4,34,70,000 representing the final 75% payment for the warrants
Total issued and subscribed share capital increased to 10,74,81,181 equity shares
The transaction demonstrates promoter commitment and provides a capital infusion of over Rs. 4.3 crore
👀 What to Watch
Investors should view the promoter's decision to convert warrants as a positive sign of confidence in the company's future. However, one should also account for the minor equity dilution resulting from the increased share count.
Virinchi Q3 Results: Consolidated Profit Returns to ₹1.60 Cr; Standalone PAT Jumps 152% YoY
Virinchi Limited reported a consolidated revenue of ₹76.89 crore for Q3 FY26, showing a 24.5% sequential recovery from Q2 but a 6.7% decline year-on-year. The company returned to a consolidated net profit of ₹1.60 crore, recovering from a massive ₹13.67 crore loss in the previous quarter. Standalone performance was notably stronger, with net profit rising 152% YoY to ₹8.38 crore. Despite the quarterly recovery, the company remains in a consolidated net loss of ₹11.70 crore for the nine-month period ending December 2025.
Key Highlights
Consolidated Revenue for Q3 FY26 at ₹76.89 crore, up 24.5% QoQ but down 6.7% YoY
Consolidated Net Profit of ₹1.60 crore vs a loss of ₹13.67 crore in Q2 FY26
Standalone Net Profit surged to ₹8.38 crore from ₹3.32 crore in the same quarter last year
SaaS Business (US Fintech) led segment performance with ₹40.20 crore revenue and ₹8.39 crore profit
Health Care Services contributed ₹25.55 crore to revenue with a segment profit of ₹3.13 crore
👀 What to Watch
Investors should track the sustainability of the return to consolidated profitability and investigate the causes of the significant losses in subsidiaries that are dragging down consolidated performance relative to standalone results. The strong performance of the SaaS/Fintech segment remains the primary value driver for the company.
Virinchi Q3 FY26: Consolidated Revenue at ₹76.89 Cr, Returns to Profitability QoQ
Virinchi Limited reported a consolidated revenue of ₹76.89 crore for Q3 FY26, marking a 24.5% recovery from the previous quarter. The company successfully returned to a consolidated net profit of ₹1.60 crore, reversing a heavy loss of ₹13.67 crore in Q2 FY26. Standalone performance was notably stronger, with net profit jumping 152% YoY to ₹8.38 crore, primarily driven by the SaaS and IT services segment. However, on a consolidated basis, both revenue and profit remain lower compared to the same quarter last year (Q3 FY25).
Key Highlights
Consolidated Revenue stood at ₹76.89 Cr, up 24.5% QoQ but down 6.7% YoY.
Returned to Consolidated Net Profit of ₹1.60 Cr vs a loss of ₹13.67 Cr in Q2 FY26.
Standalone Net Profit grew 152% YoY to ₹8.38 Cr from ₹3.32 Cr.
Consolidated Finance Costs remain high at ₹7.85 Cr for the quarter.
SaaS Business (US Fintech) remains the primary driver of standalone profitability, contributing ₹40.20 Cr to revenue.
👀 What to Watch
Investors should monitor the sustainability of the turnaround in consolidated profitability and the performance of the healthcare subsidiary which appears to be dragging group margins. While the standalone IT business is robust, high consolidated finance costs remain a key risk factor to watch.
Virinchi Allots 17.14 Lakh Equity Shares to Promoter Group via Warrant Conversion
Virinchi Limited has allotted 17,14,285 equity shares to Vivo Bio Tech Limited, a member of the promoter group, following the conversion of warrants issued on a preferential basis. The shares were issued at a price of Rs. 28 each, including a premium of Rs. 18 per share. The company received approximately Rs. 3.60 crore, representing the remaining 75% of the application money required for the conversion. This transaction increases the company's total paid-up equity capital to Rs. 105.41 crore.
Key Highlights
Allotment of 17,14,285 equity shares of Rs. 10 each at a premium of Rs. 18 per share
Receipt of Rs. 3,59,99,985 as the final 75% payment for warrant conversion
Shares allotted to Vivo Bio Tech Limited, part of the Promoter Group
Total paid-up share capital increased to 10,54,11,181 equity shares
👀 What to Watch
The conversion of warrants by a promoter group entity indicates long-term commitment and confidence in the company's valuation. Investors should monitor how the fresh capital infusion is utilized for business expansion or debt reduction.
Virinchi Allots 10.5 Lakh Equity Shares Following Warrant Conversion
Virinchi Limited has successfully allotted 1,050,000 equity shares of Rs. 10 each following the conversion of warrants issued on a preferential basis. The shares were issued at a price of Rs. 25 per share, which includes a premium of Rs. 15. The company received the remaining 75% of the application money, amounting to approximately Rs. 1.97 crore, from a public category investor. This conversion has increased the company's total paid-up share capital to approximately Rs. 103.70 crore.
Key Highlights
Allotment of 10,50,000 equity shares to Manumon Chettiar under the public category
Issue price fixed at Rs. 25 per share, including a premium of Rs. 15 per share
Receipt of Rs. 1,96,87,500 representing the 75% balance payment for the warrant conversion
Total subscribed share capital increased to 10,36,96,896 equity shares
👀 What to Watch
Investors should view this as a positive capital infusion that strengthens the balance sheet, despite the marginal equity dilution. Monitor how the company utilizes these funds for its healthcare or IT business segments.
Virinchi to Raise ₹7.83 Cr via Warrant Issue to Promoter in Healthcare Subsidiary
Virinchi Limited is seeking shareholder approval to issue 52.22 lakh convertible equity warrants in its wholly-owned subsidiary, Virinchi Health Care Private Limited, to the company's promoter, Mr. Viswanath Kompella. The warrants are priced at ₹15 each, valuing the healthcare subsidiary at an enterprise value of ₹312.08 crore. Upon conversion, the promoter's stake in the subsidiary will rise to a maximum of 49%, while Virinchi Limited will retain a controlling 51% stake. This move aims to infuse capital into the healthcare arm while maintaining management control by the parent company.
Key Highlights
Issue of 52,22,000 convertible warrants in Virinchi Health Care Private Limited to Promoter Viswanath Kompella.
Warrants priced at ₹15 per unit, aggregating to a total investment of approximately ₹7.83 crore.
Healthcare subsidiary valued at an enterprise valuation of ₹312.08 crore by an IBBI-registered valuer.
Parent company Virinchi Limited to reduce stake from 100% to a minimum of 51% post-conversion.
Warrants are convertible within 36 months with 25% of the price payable upfront.
👀 What to Watch
Investors should evaluate the fairness of the ₹312.08 crore valuation for the healthcare subsidiary and the impact of the parent company's diluted ownership. While the promoter's capital infusion is a sign of commitment, the transition from a 100% subsidiary to a 51% joint-controlled entity is a significant structural change.
